May 13, 2021 — Estimates of excess deaths, defined as the number of persons who have died from all causes, above the expected number of deaths for a given place and time, can provide a comprehensive account of mortality likely related to the COVID-19 pandemic, including deaths that are both directly and indirectly associated with COVID-19.

May 13, 2021 — PolyVascular, leading the effort to improve children's lives with a novel polymeric transcatheter valve (PTV) for children, announced that it was awarded a $2 million Small Business Innovation Research (SBIR) Phase II grant earlier this year to bring its polymeric stent-mounted valve (SMV) to clinical

May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization.

May 12, 2021 — According to the British Heart Foundation, heart and circulatory diseases cause more than a quarter (27 percent) of all deaths in the UK, which equates to more than 160,000 deaths each year — or one death every three minutes.

May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending thoracic aortic aneurysm or

May 12, 2021 — Galaxy Medical and Japan Lifeline announced an exclusive distribution agreement for the Alpha1 ablation catheter in the United States, developed by Japan Lifeline for use with the Galaxy Centauri Pulsed Electric Field (PEF) System.  Under the terms of the agreement, Galaxy will pursue U.S. regulatory approval for Alpha1 in support of eventual commercialization of the CENTAURI PEF System.

May 12, 2021 — HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced that the National Institute of Health and Care Excellence (NICE) has renewed its support for the use of its AI-powered

The BioCardia cardiac stem cell CardiAMP trial is a Phase III study looking at the efficacy of using stem cells to improve heart function in heart failure patients. It is the first trial for this technology to reach Phase III trial.

Heart failure remains an unheralded global pandemic, costing society billions of dollars each year.[1,2] Projections indicate that the incidence of heart failure will continue to increase.[3] The unprecedented growth in cardiac failure in aging populations will challenge existing systems of care and should cause us to re-examine adjunctive and alternative types of therapy.

May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE) have joined the International Contrast Ultrasound Society (ICUS) in recognizing the relatively low risk and important clinical benefits of ultrasound contrast agents (UCAs), which

May 11, 2021 — Patients hospitalized with COVID-19 may be at risk of developing heart failure even if they do not have a previous history of heart disease or cardiovascular risk factors, a new Mount Sinai study shows. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now